Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.6 |
mRNA | XMD8-92 | GDSC1000 | pan-cancer | AAC | -0.025 | 0.6 |
mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
mRNA | paclitaxel | UHNBreast | pan-cancer | AAC | -0.17 | 0.6 |
mRNA | Docetaxel | CTRPv2 | pan-cancer | AAC | -0.025 | 0.6 |
mRNA | AGK-2 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
mRNA | JW-7-52-1 | GDSC1000 | pan-cancer | AAC | -0.026 | 0.6 |
mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | 0.024 | 0.6 |
mRNA | hyperforin | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |